Digistain

🌟 Meet Our Esteemed Panelist for "Leading the Change: Spinoff Success Stories and the EU Champions Driving Innovation"! 🚀

We are delighted to introduce Dr. Hemmel Amrania PhD Breast Cancer Diagnostics, a distinguished innovator and CEO of Digistain, as one of our esteemed panelists for this inspiring session. 🤝

📅 Session Date & Time: 28 September 2023, 13:30 - 14:30

Dr. Hemmel Amrania's remarkable journey in science and innovation has left a profound impact on the field of healthcare. Holding a degree in maths and physics from Imperial College London, a Masters in Optics and Photonics from Université Paris XI, and a PhD on the biomedical applications of ultrafast laser spectroscopy, Hemmel has demonstrated exceptional dedication to advancing medical diagnostics. 🎓🌍

During his PhD, Hemmel patented a groundbreaking method to grade tumor biopsies without subjective bias. His pioneering work was recognised with the President’s Award for Outstanding Research at Imperial College, followed by prestigious honours like the Royal Society Innovation Prize and the Cancer Research Pioneer Award. 🏆💡

While working on clinical trials at Charing Cross Hospital, Hemmel witnessed firsthand the significant economic and patient care challenges that breast oncologists faced in determining cancer recurrence risk. Motivated to make a difference, he founded Digistain and developed its innovative technology—a digital AI-based approach that revolutionises the assessment of cancer biopsies. 🏥🚀

Digistain, a Y Combinator and Harvard-backed technology company spun out of Imperial College, has transformed a slow and expensive wet lab testing process into a fast, cost-effective digital solution. This advancement enables hospitals worldwide to conduct essential tests quickly, easily, and affordably using their existing equipment. Driven by a commitment to global health equity, Digistain empowers marginalised communities by providing access to a new standard of care previously unattainable. 🌐🌍

❕ Register here: https://spinoff.bg

Don't miss the opportunity to engage with Dr. Hemmel Amrania and gain insights into his transformative journey and the impact of innovation on healthcare. Join us at the Spinoff Conference & Horizon Europe Info Day on 28-29 September 2023 in Sofia, Bulgaria! 🇧🇬🌐

Sam Womack on her cancer journey, 'brutal' treatment and how life has changed EastEnders actress Sam Womack on the brutality of her breast cancer journey, new treatment and her return to work.

Team Digistain with Prof Sir Mike Dixon OBE at the American Society of Breast Surgeons Annual Symposium this year where we were Honored to be selected for the Top Ten clinical study presentations. It’s great to be recognised for our work to eliminate healthcare inequalities around the world.

Honoured today to be offered a place on NHS Oxford’s UK Access Program! A great step towards achieving even further adoption in the UK and to enable us to reach and help more patients as we help the UK slash the post-Covid cancer treatment waiting times.

Delighted to be shortlisted as a finalist at the Medilink Business Awards 2023 for not one but two categories! Advances in Digital Health and for Achievement in Exporting of British Tech. Looking forward to the final announcements! .

Excited to be featured in the Indian national news this weekend as we help economically challenged patients get access to a new standard of care that they could only dream of before!

https://lnkd.in/ek6PhKAp

How this AI tool for breast cancer can tell you if you need chemotherapy or not Invention by UK-based Indian origin scientist, Dr Hemmel Amrania, detects the need for chemotherapy in cancer patients faster and cheaper, at one-fourth of current costs. It aims to ensure equity in treatment protocols

Thankful for the opportunity to unveil our latest clinical study at San Antonio Breast Cancer Symposium this week!

Proud to attend the Institute of Physics ceremony over the weekend to collect our Digistain business award. Great to be recognised for crossing the chasm to translate lab research to real-world clinical utility. As many researchers out there will know this is such an onerous challenge and more support from University Tech Transfer Offices is needed to ensure promising technologies do not fall by the wayside. A humble thanks for the recognition as we learned from the CEO that only 1 in 76 of businesses awarded this accolade have ever failed. A special shout-out to Zamzam Al-Khalili and Prof Chris Phillips for their hard work and support in making this happen.

Pleased to be on the radio again talking about our mission here at Digistain to eliminate the inequality of care.

Dr Hemmel Amrania (Digistain) BBC Radio Three Counties Interview Pleased to be on the radio again talking about our mission here at Digistain’s to eliminate the inequality of care.

Excited to be in Boston, MA for the Med Tech Conference. Here Digistain is keeping up to date on the latest health-tech updates and regulatory changes

On the BBC today talking about British patient access to emerging technologies and the challenges health-tech companies face in the widespread adoption of their technologies in the UK.

Dr Hemmel Amrania (Digistain) BBC Radio Interview On the BBC today talking about British patient access to emerging technologies and the challenges health-tech companies face in the widespread adoption of th...

Pat Whitworth ex-Chairman of the American Society of Breast Surgeons and Committee member of TME presents Digistain as a “game changer with its highly disruptive technology” with its ability to streamline throughout in evaluating patient risk for hormone-positive breast cancer.

is proud to present to an audience of thought leaders in breast care at TME 2022
as they discussed its disruptive potential.

https://www.imperial.ac.uk/news/240611/rapid-breast-cancer-screening-technology-could/

Many women with don’t need . Identifying them quickly and tailoring their treatment will be possible thanks to a system developed by startup DigiStain with technology invented at Imperial College London

Rapid breast cancer screening technology could stop unnecessary chemotherapy | Imperial News | Imperial College London Startup company Digistain has used technology developed at Imperial to help doctors choose the best treatment for women with breast cancer.

https://www.youtube.com/watch?v=vjfM4onfCX0

DigiStain’s CEO Dr Hemmel Amrania LIVE on Sky NEWS UK

DigiStain on SkyNEWS UK News

The Sun highlighting a new British-invented breakthrough tool in the treatment of breast cancer care. diagnostic AI technology could prevent thousands of deaths and reduce the use of chemo in organisations like NHS, saving millions.
https://t.co/qUnO4vIjeA

Revolutionary AI scanner could transform treatment for cancer patients BREAST cancer patients could avoid gruelling chemotherapy thanks to a cutting-edge AI scanner. Inventors of the Digistain artificial intelligence technology say it can tell with 99 per cent accurac…

The Mail On Sunday and Daily Mail breaking news of a revolutionary new breast cancer technology from DigiStain® which could save lives - and millions of pounds.

AI breakthrough could spare THOUSANDS from breast cancer chemotherapy Scientists believe the new method could save the NHS millions of pounds each year because it offers a quicker and cheaper way of determining whether the disease is likely to return after surgery.

Delighted to be invited to deliver a keynote at the expert speakers panel at the Annual Biomarker and Companion Diagnostics conference.

"The 4th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 6th - 7th October 2022 in London, UK would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers.

Absolutely beaming to learn that Innovate UK SMART committee chose to fund Digistain - This is one of UK's most fiercely competitive funding calls and it's wonderful to have Digistain get this stamp of approval by the UK Government!

Smart is Innovate UK’s responsive grant funding programme. It has focused eligibility criteria and scope to support SMEs and their partners to develop disruptive innovations with significant potential for a rapid, economic return to the UK.

Innovate UK, part of UK Research and Innovation, is investing up to £25 million in the best game-changing, and world-leading ideas, designed for swift, successful commercialisation. Ideas need to be genuinely new and novel, not just disruptive within their sector

Proud to be presenting our clinical data at ESMO!

The European Society for Medical Oncology (ESMO) is the leading organisation for cancer education and information, supporting the oncology community’s work.

Presenting with promising companies of the future at Spinoff Bulgaria!

The first edition of Spinoff Bulgaria Conference offers an exciting opportunity for business, academia, investors, healthcare and government stakeholders to get together and discuss the future of innovation. The programme consists of plenary sessions with Q&As, panels and active networking and matchmaking opportunities

Huge thanks to European Government backed Sofia Angels Ventures for their investment in Digistain.

The €13M venture fund supported by European Investment Fund (EIF) for angel and private co-investment, Sofia Angels Ventures announced that it had made its fourth investment, backing UK-based medtech startup Digistain. The funding will aim to help the company receive FDA approval, as well as complete new clinical trials, further build up the team and start commercial activities.

Digistain is invited to TME after party in Vegas (April 2022)

With Mammaprint CMO - William Audeh at the TME afterparty in Vegas.

Digistain is invited to TME meeting in Vegas (April 2022)

TME hosted its Annual Research Reception at The American Society of Breast Surgeons 23rd Annual Meeting in Las Vegas on 8 April 2022. This year's reception was dedicated to TME Founder, Emeritus, Mark Gittleman MD.

Digistain presenting our latest clinical data at the American Society of Breast Surgeons Meeting - Las Vegas. (April 2022)

Together, we discussed the latest research, surgical innovations, and practice-changing information for breast surgeons while enjoying time networking with our colleagues. Reuniting our community to connect and learn together made the Society’s 23rd Annual Meeting special.

Proud to showcase our clinical data at the interdisciplinary conference - the National Consortium of Breast Cancers - Las Vegas (March 2022)

This year’s program highlights the interdisciplinary team and brings together experts in breast surgery, oncology, radiology, pathology, nursing, administration, navigation, and psycho-oncology, to share cutting-edge updates from prevention, early detection and survivorship.

Announcing our new team member - Darius Francescatti, the decorated breast onco-surgeon who brings to Digistain 20+ years of experience in breast cancer management.

Prof Darius Francescatti MD, JD, FACS
Darius is a general surgeon in Chicago, Illinois. He received his medical degree from Loyola University Chicago Stritch School of Medicine and has been in practice limited to breast oncology for more than 20 years. His professional interests are directed at advancing the technologies that will have an impact on better surgical outcomes for breast cancer patients. His interests
have included the early adoption of breast ultrasound, ductal Lavage and ductoscopy, cryo and laser ablation of breast tumours, accelerated partial breast irradiation and intraoperative radiotherapy and the use of genomic molecular subtyping of breast cancer for which he was an early adopter of Agendia’s
Mammaprint.

Honoured to get a mention in TechCrunch - the respected voice in high-tech news! (Aug/2021)

"Here are all the companies from Y Combinator’s Summer 2021 Demo Day, Part 1. Today Y Combinator kicked off the Demo Day cycle for its Summer 2021 cohort. The collection of early-stage startups on day one-of-two alone numbered in the hundreds.

Digistain: One of several startups in this cohort taking on the cancer market, Digistain wants to use infrared scanning to better understand which breast cancer patients are truly a fit for chemotherapy. Its view is that more folks than needed get chemotherapy, which is not only expensive but can actually kill you. I am not an expert on regulatory approval, but using tech to avoid taking poison juice to the jugular sounds pretty great."

Proud to have our breakthrough breast cancer technology funded by Y Combinator - the Silicon Valley investor whose international status is second to none! ( AUG/2021)

Since 2005, Y Combinator has funded over 3,000 companies and worked with over 6,000 founders. Every 6 months over 10,000 companies apply to participate in our accelerator and we typically have a 1.5% - 2% acceptance rate.
In August 2021, Digistain has secured funding from Y Combinator. Money raised $125k